SG11202105889YA - Cxcr7 inhibitors for the treatment of cancer - Google Patents
Cxcr7 inhibitors for the treatment of cancerInfo
- Publication number
- SG11202105889YA SG11202105889YA SG11202105889YA SG11202105889YA SG11202105889YA SG 11202105889Y A SG11202105889Y A SG 11202105889YA SG 11202105889Y A SG11202105889Y A SG 11202105889YA SG 11202105889Y A SG11202105889Y A SG 11202105889YA SG 11202105889Y A SG11202105889Y A SG 11202105889YA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- cxcr7
- inhibitors
- cxcr7 inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862778605P | 2018-12-12 | 2018-12-12 | |
| PCT/US2019/065600 WO2020123582A1 (en) | 2018-12-12 | 2019-12-11 | Cxcr7 inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105889YA true SG11202105889YA (en) | 2021-07-29 |
Family
ID=71073777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105889YA SG11202105889YA (en) | 2018-12-12 | 2019-12-11 | Cxcr7 inhibitors for the treatment of cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11464786B2 (en) |
| EP (1) | EP3893882A4 (en) |
| JP (1) | JP2022512367A (en) |
| KR (1) | KR20210102338A (en) |
| CN (1) | CN113194956A (en) |
| AU (1) | AU2019398198A1 (en) |
| BR (1) | BR112021011222A2 (en) |
| CA (1) | CA3122100A1 (en) |
| IL (1) | IL283885A (en) |
| MA (1) | MA54465A (en) |
| MX (1) | MX2021006915A (en) |
| SG (1) | SG11202105889YA (en) |
| WO (1) | WO2020123582A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102196374B1 (en) | 2012-11-29 | 2020-12-31 | 케모센트릭스, 인크. | Cxcr7 antagonists |
| AU2019398198A1 (en) * | 2018-12-12 | 2021-07-08 | Chemocentryx, Inc. | CXCR7 inhibitors for the treatment of cancer |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS536156B2 (en) | 1972-10-30 | 1978-03-04 | ||
| ES2271967T3 (en) | 1996-03-29 | 2007-04-16 | Duphar International Research B.V | PIPERAZINE AND PIPERIDINE COMPOUNDS. |
| WO2001002392A1 (en) | 1999-06-30 | 2001-01-11 | Bristol-Myers Squibb Company | Heterocyclic aminopyrrolidine derivatives as melatonergic agents |
| BR0112631A (en) | 2000-07-20 | 2003-09-23 | Neurogen Corp | A compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, package, methods of reducing the calcium conductance of a capsaicin receptor and treating a mammal and use of a compound. |
| DK1399483T3 (en) | 2001-01-05 | 2010-08-02 | Pfizer | Antibodies to insulin-like growth factor receptor I |
| WO2002094799A2 (en) | 2001-05-22 | 2002-11-28 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
| US7169750B2 (en) | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| US7871619B2 (en) | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| ES2322252T3 (en) | 2002-03-13 | 2009-06-18 | Janssen Pharmaceutica Nv | AMINODERIVED AS NEW HISTONA-DEACETILASA INHIBITORS. |
| WO2004009587A1 (en) | 2002-07-22 | 2004-01-29 | Orchid Chemicals & Pharmaceuticals Ltd | Oxazolidinone derivatives as antibacterial agents |
| JP2004203871A (en) | 2002-12-13 | 2004-07-22 | Yamanouchi Pharmaceut Co Ltd | Medicinal composition |
| WO2005023771A1 (en) | 2003-09-05 | 2005-03-17 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonist and medical use thereof |
| WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
| WO2005074645A2 (en) | 2004-02-03 | 2005-08-18 | Chemocentryx, Inc. | Methods and compositions for modulating angiogenesis |
| AU2006230674A1 (en) | 2004-03-18 | 2006-11-16 | The Brigham And Women's Hospital, Inc. | Methods for the Treatment of Synucleinopathies |
| EP1637529A1 (en) | 2004-09-20 | 2006-03-22 | 4Sc Ag | Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof |
| US7601745B2 (en) | 2004-09-27 | 2009-10-13 | 4Sc Ag | Heterocyclic NF-kB inhibitors |
| US7417062B2 (en) | 2004-09-29 | 2008-08-26 | Chemocentryx, Inc. | Substituted arylamides |
| WO2006100461A1 (en) | 2005-03-23 | 2006-09-28 | Astrazeneca Ab | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY |
| AU2006263657A1 (en) | 2005-06-29 | 2007-01-04 | Chemocentryx, Inc. | Substituted N-cinnamyl benzamides |
| WO2007059108A2 (en) | 2005-11-10 | 2007-05-24 | Chemocentryx, Inc. | Substituted quinolones and methods of use |
| US8173365B2 (en) * | 2006-03-24 | 2012-05-08 | The University Of Tokyo | Method for inhibiting signal transduction, signal transduction inhibitor to be used therein and use thereof |
| CA2647678A1 (en) | 2006-03-29 | 2007-11-08 | Merck & Co., Inc. | Diazepan orexin receptor antagonists |
| WO2007115232A2 (en) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| WO2007115231A2 (en) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| AU2007272855B2 (en) | 2006-07-14 | 2013-08-01 | Merck Sharp & Dohme Corp. | Substituted diazepan orexin receptor antagonists |
| BRPI0714440A2 (en) | 2006-07-21 | 2013-04-24 | Irm Llc | itpkb inhibitor compound, use thereof and pharmaceutical composition |
| WO2008020229A2 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Antibacterial pyrrolecarboxamides |
| US8088895B2 (en) | 2006-10-18 | 2012-01-03 | Chemocentryx, Inc. | Antibodies that bind CXCR7 epitopes |
| PE20081229A1 (en) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | DIAZEPAM OREXIN RECEPTOR ANTAGONISTS REPLACED |
| CN101679297B (en) | 2006-12-08 | 2012-01-11 | 埃克塞利希斯股份有限公司 | LXR and FXR modulators |
| TW200833711A (en) | 2006-12-22 | 2008-08-16 | Genentech Inc | Antibodies to insulin-like growth factor receptor |
| US20080293711A1 (en) | 2007-03-08 | 2008-11-27 | Clark Michael P | Chemokine receptor modulators |
| TW200944523A (en) | 2008-02-08 | 2009-11-01 | Organon Nv | (Dihydro)pyrrolo[2,1-a]isoquinolines |
| MX2011004490A (en) | 2008-11-04 | 2011-07-20 | Chemocentryx Inc | Modulators of cxcr7. |
| US8853202B2 (en) * | 2008-11-04 | 2014-10-07 | Chemocentryx, Inc. | Modulators of CXCR7 |
| GB0822981D0 (en) | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| CN103119045B (en) | 2010-08-20 | 2016-02-17 | 和记黄埔医药（上海）有限公司 | Pyrrolopyrimidine compounds and uses thereof |
| AU2011302196B2 (en) * | 2010-09-14 | 2016-04-28 | Exelixis, Inc. | Inhibitors of PI3K-delta and methods of their use and manufacture |
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
| CN103732592A (en) | 2011-04-21 | 2014-04-16 | 默沙东公司 | Insulin-like growth factor-1 receptor inhibitors |
| KR102196374B1 (en) | 2012-11-29 | 2020-12-31 | 케모센트릭스, 인크. | Cxcr7 antagonists |
| US9260527B2 (en) | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
| AU2019398198A1 (en) * | 2018-12-12 | 2021-07-08 | Chemocentryx, Inc. | CXCR7 inhibitors for the treatment of cancer |
-
2019
- 2019-12-11 AU AU2019398198A patent/AU2019398198A1/en active Pending
- 2019-12-11 EP EP19894634.5A patent/EP3893882A4/en active Pending
- 2019-12-11 BR BR112021011222-7A patent/BR112021011222A2/en unknown
- 2019-12-11 CN CN201980083136.4A patent/CN113194956A/en active Pending
- 2019-12-11 KR KR1020217021338A patent/KR20210102338A/en unknown
- 2019-12-11 MX MX2021006915A patent/MX2021006915A/en unknown
- 2019-12-11 SG SG11202105889YA patent/SG11202105889YA/en unknown
- 2019-12-11 JP JP2021533313A patent/JP2022512367A/en active Pending
- 2019-12-11 US US16/710,160 patent/US11464786B2/en active Active
- 2019-12-11 CA CA3122100A patent/CA3122100A1/en active Pending
- 2019-12-11 MA MA054465A patent/MA54465A/en unknown
- 2019-12-11 WO PCT/US2019/065600 patent/WO2020123582A1/en unknown
-
2021
- 2021-06-10 IL IL283885A patent/IL283885A/en unknown
-
2022
- 2022-07-29 US US17/816,281 patent/US20230100102A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020123582A1 (en) | 2020-06-18 |
| EP3893882A1 (en) | 2021-10-20 |
| BR112021011222A2 (en) | 2021-08-24 |
| MA54465A (en) | 2021-10-20 |
| MX2021006915A (en) | 2021-08-24 |
| US20200188410A1 (en) | 2020-06-18 |
| US11464786B2 (en) | 2022-10-11 |
| IL283885A (en) | 2021-07-29 |
| JP2022512367A (en) | 2022-02-03 |
| EP3893882A4 (en) | 2022-08-31 |
| AU2019398198A1 (en) | 2021-07-08 |
| KR20210102338A (en) | 2021-08-19 |
| CN113194956A (en) | 2021-07-30 |
| CA3122100A1 (en) | 2020-06-18 |
| US20230100102A1 (en) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3781564C0 (en) | Pyridazine derivatives for the treatment of cancer | |
| HK1247202A1 (en) | Compounds for the treatment of cancer | |
| EP3548071A4 (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| IL264674B1 (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| IL279260A (en) | Kdm1a inhibitors for the treatment of disease | |
| IL275496A (en) | Glycolate oxidase inhibitors for the treatment of disease | |
| IL261047A (en) | Taf1 inhibitors for the therapy of cancer | |
| IL268676A (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11202011117VA (en) | Treatment of cancer | |
| EP3503887A4 (en) | Combinations for the treatment of cancer | |
| EP3490561A4 (en) | Combinations for the treatment of cancer | |
| SG11202010793UA (en) | Methods of treating cancer | |
| IL274198A (en) | Use of nox inhibitors for treatment of cancer | |
| IL285807A (en) | Immunotherapy for the treatment of cancer | |
| EP3630080A4 (en) | Use of ezh2 inhibitors for treating cancer | |
| IL283885A (en) | Cxcr7 inhibitors for the treatment of cancer | |
| EP3548007A4 (en) | Methods for the treatment of cancer | |
| IL288522A (en) | Egfr inhibitor for the treatment of cancer | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| EP3285769A4 (en) | Selective pfkfb4 inhibitors for the treatment of cancer | |
| IL281600A (en) | Methods of treating cancer | |
| IL277981A (en) | Methods of treating cancer | |
| IL282313A (en) | Abituzumab for the treatment of colorectal cancer | |
| EP3630754B8 (en) | Isoindoline-acetylene compounds for the treatment of cancer | |
| EP3615052A4 (en) | Use of hcn inhibitors for treatment of cancer |